Rating Watching: Heska Corp (NASDAQ:HSKA) Moves On The Benchmark Company Initiation. How Much Its Worth?

November 29, 2016 - By Dolores Ford

Rating Watching: Heska Corp (NASDAQ:HSKA) Moves On The Benchmark Company Initiation. How Much Its Worth?

Why The Benchmark Company Gives Heska Corp (NASDAQ:HSKA) $78 Price Target

The Benchmark Company released in an analysts note that it began coverage on Heska Corp (NASDAQ:HSKA) stock, with a Buy rating and a $78 target price.

Heska Corp (NASDAQ:HSKA) Ratings Coverage

Out of 2 analysts covering Heska Corp (NASDAQ:HSKA), 0 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 0 are positive. Heska Corp has been the topic of 3 analyst reports since August 25, 2015 according to StockzIntelligence Inc. The stock has “Hold” rating given by TheStreet on Tuesday, August 25. The stock has “Hold” rating given by Gabelli on Thursday, August 4. The company was initiated on Friday, April 1 by CL King.

About 40,582 shares traded hands. Heska Corp (NASDAQ:HSKA) has risen 132.87% since April 26, 2016 and is uptrending. It has outperformed by 127.61% the S&P500.

Analysts await Heska Corp (NASDAQ:HSKA) to report earnings on March, 2. They expect $0.37 earnings per share, up 32.14% or $0.09 from last year’s $0.28 per share. HSKA’s profit will be $2.52 million for 46.14 P/E if the $0.37 EPS becomes a reality. After $0.45 actual earnings per share reported by Heska Corp for the previous quarter, Wall Street now forecasts -17.78% negative EPS growth.

Insitutional Activity: The institutional sentiment decreased to 1.36 in 2016 Q2. Its down 0.18, from 1.54 in 2016Q1. The ratio is negative, as 6 funds sold all Heska Corp shares owned while 29 reduced positions. 24 funds bought stakes while 30 increased positions. They now own 4.56 million shares or 4.63% more from 4.36 million shares in 2016Q1.

Gsa Prtnrs Llp has invested 0.17% of its portfolio in Heska Corp (NASDAQ:HSKA). Deutsche Comml Bank Ag reported 976 shares or 0% of all its holdings. Geode Capital Lc reported 43,308 shares or 0% of all its holdings. The New York-based Blackrock Incorporated has invested 0% in Heska Corp (NASDAQ:HSKA). Barclays Public Ltd Co accumulated 2,500 shares or 0% of the stock. Nationwide Fund reported 3,833 shares or 0% of all its holdings. The California-based Schwab Charles Investment Management Incorporated has invested 0% in Heska Corp (NASDAQ:HSKA). Moreover, Teton has 0.13% invested in Heska Corp (NASDAQ:HSKA) for 38,000 shares. Royal Financial Bank Of Canada accumulated 380 shares or 0% of the stock. Bnp Paribas Arbitrage holds 0% of its portfolio in Heska Corp (NASDAQ:HSKA) for 241 shares. Blackrock Inv Ltd Limited Liability Company reported 23,140 shares or 0% of all its holdings. Blackrock Institutional Trust Communication Na last reported 220,714 shares in the company. Adams Diversified Equity Fund Inc has invested 0.02% of its portfolio in Heska Corp (NASDAQ:HSKA). Walleye Trading reported 400 shares or 0% of all its holdings. Invesco Limited holds 12,326 shares or 0% of its portfolio.

Insider Transactions: Since July 1, 2016, the stock had 0 buys, and 15 insider sales for $6.68 million net activity. The insider Wilson Kevin S. sold 5,960 shares worth $240,008. $7,028 worth of Heska Corp (NASDAQ:HSKA) was sold by McMahon John on Wednesday, August 24. $820,000 worth of shares were sold by NAPOLITANO JASON A on Thursday, July 7. Asakowicz Steve sold $246,864 worth of stock. Another trade for 9,998 shares valued at $601,051 was sold by McGinley Michael J. Lippincott Rod sold $324,258 worth of stock or 5,000 shares.

Heska Corporation develops, manufactures, markets, sells and supports veterinary products. The company has a market cap of $465.99 million. The Firm focuses on the canine and feline companion animal health markets. It has a 54.97 P/E ratio. The Company’s divisions include Core Companion Animal Health segment, which includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, and single use services and products, such as heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing, and Other Vaccines, Pharmaceuticals and Products segment, which includes private label vaccine and pharmaceutical production, primarily for cattle but also for other animals, including small mammals.

According to Zacks Investment Research, “Heska Corporation is focused on the discovery, development and marketing of companion animal health products. In addition to manufacturing certain of companion animal products, the company’s primary manufacturing subsidiary, Diamond Animal Health, Inc., also manufactures animal health vaccine products which are marketed and distributed by third parties. In addition to manufacturing veterinary allergy products for marketing and sale by the company, subsidiaries, Center Laboratories, Inc. and CMG-Heska Allergy Products S.A., also manufacture and sell human allergy products.”

HSKA Company Profile

Heska Corporation, incorporated on March 27, 1997, develops, makes, markets, sells and supports veterinary products. The Firm is focused on the canine and feline companion animal health markets. The Firm operates in two divisions, which include Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, and single use services and products, such as heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing. The OVP segment includes private label vaccine and pharmaceutical production, primarily for cattle but also for other animals, including small mammals. It sells veterinary diagnostic and other specialty veterinary products. The Company’s offerings include blood testing instruments and supplies, digital imaging products, software and services, and single use services and products, such as in-clinic heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>